期刊
SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-021-98769-0
关键词
-
资金
- Swiss National Science Foundation (SNSF) [P2ZHP3_181506]
- SNSF [186708]
- Walter and Gertrud Siegenthaler Postdoctoral Fellowship
- Hartmann Mueller Foundation
- Kurt und Senta Herrmann Stiftung
- Forschungskredit of the University of Zurich [FK-19-048]
- Swiss National Science Foundation (SNF) [P2ZHP3_181506] Funding Source: Swiss National Science Foundation (SNF)
The study investigated 75 peripheral inflammatory markers in patients with MDD, SZ and healthy controls, identifying CCL20 and TRAIL as inflammatory markers with significant group differences. TRAIL was elevated in both MDD and SZ, while CCL20 was specifically increased in SZ. No significant group differences were found in hsCRP.
Schizophrenia (SZ) and major depressive disorder (MDD) are severe mental disorders, which have been associated with alterations of the peripheral inflammatory network. However, studies for both disorders have not been fully consistent and have focused on few canonical markers with high relevance to the innate immune system, while the role of the adaptive immune system is studied less. Furthermore, it is unclear to what extent inflammatory abnormalities are diagnosis-specific or transdiagnostic. The purpose of this study was to investigate 75 peripheral inflammatory markers including the acute phase protein high-sensitivity C-reactive protein (hsCRP) in patients with MDD (n=37), SZ (n=42) and healthy controls (HC) (n=17), while considering possible confounders and correcting rigorously for multiple testing in group comparisons. We identified C-C chemokine ligand 20 (CCL20) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as the inflammatory markers with significant group differences after controlling for multiple comparisons and adjusting for BMI, sex and smoking as confounders. TRAIL was elevated in both MDD and SZ compared to HC. CCL20 was specifically increased in SZ compared to MDD and HC. There were no significant group differences in hsCRP after correcting for multiple testing. Finally, we observed no significant correlations among CCL20, TRAIL and CRP. TRAIL is a transdiagnostic marker for SZ and MDD, with both markers being independent from CRP and body mass index (BMI). CCL20 may be a novel and specific biomarker of schizophrenia, but an influence of antipsychotic medication cannot be excluded. Identifying novel markers in mental disease bears the potential for future research towards novel treatment strategies by modifying inflammation-related processes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据